Day Two Morning Sessions

Android vs iOS

Listening to the Abbott presentation and corresponding Q&A a few things are becoming clearer in the expanding CGM market.

1. The company noted there are now over 1 million patients using the Libre with 200,000 domestically and 800,000 overseas. This has generated sales approaching $1 Billion.

2. There is no question that Abbott is committed to providing Libre at a lower price point than Dexcom, noting several times that Libre is an “affordable” CGM.

3. In an interesting twist the company made a point to mention that getting the Libre to work is . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.